Page 451 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Chose AS vs.
randomization
to available
treatments
Mills 173 Patient comparison of 2001- 318 not reported regular Multivariable 1. SES and baseline anxiety
2006 preferences 180 men who 2004 PSA logistic associated with selecting
16774847 refused regression treatment: per decrease in SES
randomization predicting from I to V, OR=0.68 (CI 0.49,
but selected “selecting 0.96); P=0.03.
AS with 138 AS” vs. 2. Baseline anxiety (per unit
men “randomized increase on HAD scale) OR=0.93
randomized to AS” (CI 0.87, 0.99); P=0.04)
to AS (from adjusted for baseline score, study
ProtecT center, age (further adjustment for
study) marital status, SES had little
impact (data not shown))

Applicability limited to
predominantly white married,
middle class men 50-69 yrs
healthy for clinic testing.
Estimates are provided with 95% confidence intervals and p-values when available.
AS = active surveillance; BMI = body mass index; CI = confidence interval; DOD CPDR = Department of Defense Center for Prostate Disease Research; dx = diagnosis;
ERSPC = European Randomized Study of Screening for Prostate Cancer; FH = family history; HAD = Hospital Anxiety and Depression scale; NS = non-statistically significant;
PCOS = Prostate Cancer Outcomes Study; POC = Patterns of Care study; PRIAS = Prostate Cancer Research International: Active Surveillance study; ProtecT = Prostate Testing
for Cancer and Treatment study; PSA = prostate-specific antigen; TUMT = transurethral microwave thermotherapy of the prostate; UI = PubMed unique identifier; WW =
watchful waiting; yr = year.

C-143